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Differentiation of B cells into plasma cells requires X-box binding protein–1 (XBP-1). In the 
absence of XBP-1, B cells develop normally, but very little immunoglobulin is secreted. XBP-1 
controls the expression of a large set of genes whose products participate in expansion of the 
endoplasmic reticulum (ER) and in protein trafficking. We define a new role for XBP-1 in 
exerting selective translational control over high and sustained levels of immunoglobulin M 
(IgM) synthesis. XBP-1
 
 
 
/
 
 
 
 and XBP-1
 
 
 
/
 
 
 
 primary B cells synthesize IgM at comparable levels at 
the onset of stimulation with lipopolysaccharide or CpG. However, later there is a profound 
depression in synthesis of IgM in XBP-1
 
 
 
/
 
 
 
 B cells, notwithstanding similar levels of 
 
 
 
mRNA. In 
marked contrast, lack of XBP-1 does not affect synthesis and trafficking of other glycoproteins, 
or of immunoglobulin light chains. Contrary to expectation, degradation of proteins from the 
ER, using TCR
 
 
 
 or US11-mediated degradation of class I major histocompatibility complex 
molecules as substrates, is normal in XBP-1
 
 
 
/
 
 
 
 B cells. Furthermore, degradation of membrane 
 
 
 
 was unaffected by enforced expression of XBP-1. We conclude that in primary B cells, the 
XBP-1 pathway promotes synthesis and secretion of IgM, but does not seem to be involved in 
the degradation of ER proteins, including that of 
 
 
 
 chains themselves.
 
X-box binding protein–1 (XBP-1) is required
for differentiation of B cells into plasma cells.
XBP-1
 
 
 
/
 
 
 
 B cells develop normally to maturity,
but fail to differentiate into plasma cells (1).
XBP-1 is a key component of the unfolded
protein response (UPR)—a signaling pathway
that emanates from the ER; its activation induces
the transcription of a large number of target
genes that is believed to be essential for quality
control of newly synthesized proteins (2–4).
When proteins emerge into the ER, they
undergo posttranslational modifications, such
as N-linked glycosylation and disulfide bond
formation. These modifications, assisted by
several chaperones, are required for proper
folding and assembly of newly synthesized ER
proteins. When the amount of client proteins
exceeds the folding capacity of the ER, a state
of ER stress ensues that triggers the UPR (2).
The UPR activates corrective measures to allevi-
ate the stress conditions in the ER. In mamma-
lian cells, the UPR is driven by at least three
transducers: PKR-like endoplasmic reticulum
eIF2
 
 
 
 kinase
 
 
 
(PERK), activating transcription
factor 6 (ATF6), and IRE1 (2). When acti-
vated, PERK, a serine/threonine kinase, phos-
phorylates eIF2
 
 
 
, and so reduces the rate of
translation to attenuate the protein load in the
secretory system. ATF6, when properly en-
gaged, is cleaved and its cytosolic portion
translocates to the nucleus, where it activates
transcription of numerous target genes, including
XBP-1. IRE1, similarly to PERK, is activated by
autotransphosphorylation. Activated IRE1 splices
XBP-1 mRNA, using an unconventional mech-
anism similar to that described for Ire1p/Hac1
in yeast (5). The spliced XBP-1 mRNA gives
rise to a polypeptide comprised of the original
NH
 
2
 
-terminal DNA binding domain and an
additional transactivation domain in the COOH
terminus. Spliced XBP-1 (XBP-1s) is a potent
transcription factor that activates the expression
of ER chaperones and promotes the biogenesis
of ER membranes (4, 6–8).
Differentiation into plasma cells involves a
remarkable remodeling of the secretory path-
way. The ER undergoes massive expansion to
accommodate the large quantities of newly
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synthesized Ig, and to ensure successful assembly of the mo-
nomeric Ig subunits into multimeric complexes in prepara-
tion for secretion (9, 10). The transition of B cells into
plasma cells provokes the UPR, as indicated by XBP-1
mRNA splicing and the up-regulation of ER chaperones
(10). Furthermore, ectopic expression in mature B cells of
XBP-1s, but not the unspliced form of XBP-1, promotes
expansion of the ER, an increase in mitochondrial mass and
total organelle content, and an overall increase in cell size (11).
When proteins fail to assemble or fold correctly in the
ER, a quality control mechanism identifies these misfits and
targets them for degradation. The process of ER degradation
often entails dislocation of the substrates from the ER to the
cytoplasm, where the misfolded protein is ubiquitinated and
destroyed by the proteasome. The UPR in yeast is linked
tightly to degradation of ER proteins. Strains deleted for
genes encoding Ire1p or Hac1p cannot properly dispose of
misfolded ER proteins (12, 13). By analogy with yeast, cir-
cumstantial evidence implicates XBP-1 in control of degra-
dation of misfolded ER proteins in mammalian cells (14).
Transcriptional profiling analysis that compared WT and
XBP-1
 
 
 
/
 
 
 
 B cells indicated that XBP-1 exerts control over
many genes implicated in the degradation of ER proteins,
including ER degradation enhancing 
 
 
 
-mannosidase-like
protein (EDEM; an ER lectin required for degradation of
certain misfolded substrates), E3 ubiquitin ligases, protea-
some subunits, and many others (11).
Despite the seemingly crucial role of XBP-1 in setting the
proper conditions for the secretory pathway in plasma cells,
evidence that directly positions XBP-1 in the ER degrada-
tion pathway is missing. Therefore, it is unclear whether
XBP-1 is essential for quality control in the ER. In addition,
the contribution of XBP-1 to protein trafficking in the secre-
tory pathway of mature and activated B cells is not known.
Here, we investigated the role of XBP-1 in the biosyn-
thesis and secretion of IgM, and in supporting the degrada-
tion of misfolded or misassembled ER proteins in primary
plasmablasts. We show that XBP-1
 
 
 
/
 
 
 
 and XBP-1
 
 
 
/
 
 
 
 B cells
synthesize IgM at comparable levels at the onset of mitogenic
stimulation with LPS or CpG. However, over a 3-d period
of stimulation there is a profound depression of IgM synthesis
and secretion in XBP-1
 
 
 
/
 
 
 
 B cells, notwithstanding similar
 
 
 
mRNA levels in WT and XBP-1
 
 
 
/
 
 
 
 B cells. The lack of
XBP-1 does not affect synthesis or trafficking of other glyco-
proteins or of Ig light chains, nor does it hamper their degra-
dation. We conclude that in primary B cells, the XBP-1
pathway specifically promotes synthesis and secretion of IgM,
a new example of translational control, but does not seem to
be involved in the degradation of ER proteins.
 
RESULTS
XBP-1 controls plasmablasts’ cell size
 
Imposition of expression of XBP-1s in B cell lines, such as
RAJI and WEHI231, expands their ER and increases their
overall size (11). We investigated whether the absence of
XBP-1 would affect the cell size in the course of B cell stim-
ulation by the B cell mitogens, CpG (15), or LPS (16).
XBP-1
 
 
 
/
 
 
 
 and WT (XBP-1
 
 
 
/
 
 
 
) primary B cells were puri-
fied and stimulated with CpG. We saw no significant cell
death and no difference in size for the first 48 h of culture
(Fig. 1, two top). At day 3, the size of WT cells was larger
than that of XBP-1
 
 
 
/
 
 
 
. At day 4, viability of the cells was
reduced markedly and decreased to 
 
 
 
50% (Fig. 1 A, bot-
tom), a parameter independent of the absence of XBP-1.
We analyzed the splicing of XBP-1 mRNA in response to
the stimulation of B cells with CpG. Splicing of XBP-1
mRNA was induced at day 2 of CpG stimulation, and con-
tinued until termination of the experiment at day 4 (Fig. 1
B). This level of splicing was comparable to the level in-
duced by treatment of naive B cells with 1 
 
 
 
g/ml tunicamy-
cin for 4 h. Similar results were obtained with LPS stimula-
tion, which yielded a larger increase in cell size than did
Figure 1. XBP-1 controls plasmablasts’ cell size. (A) WT or XBP-1 /  
B cells were purified from splenocytes by magnetic depletion with anti-CD43. 
Cells were plated at 106 cells/ml and stimulated with CpG. Flow cytometry 
analysis was performed every 24 h, and live cells were gated based on their 
forward and side scattering. Cells were replated at 106 cells/ml density and 
were analyzed the next day. Line graphs of the gated cells at the forward 
scatter channel (FSC) are shown in the right column. Gray, WT cells; white, 
XBP-1 /  cells. The percentage of dead cells is indicated. (B) Cells were 
stimulated with CpG for 4 d. RNA was extracted at the indicated times, 
and splicing of XBP-1 mRNA was analyzed by RT-PCR. Tunicamycin treat-
ment (1 g/ml, 4 h) of naive B cells was used as a positive control. 
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CpG (unpublished data). We conclude that in the course of
primary B cell stimulation, XBP-1 splicing promotes the in-
crease in the overall cell size, but does not promote cell sur-
vival. Therefore, day 3 of stimulation was selected as the op-
timal time point for biochemical analyses of the primary
plasmablasts, because at this time point, the cells show opti-
mal survival and the effect of XBP-1 deficiency on B cell
size is overt.
 
High levels of biosynthesis and secretion of IgM 
require XBP-1
 
We followed the biosynthesis of IgM in the course of B cell
stimulation with LPS or CpG by pulse-chase analysis. The
initial level of synthesis of IgM was similar for LPS- or
CpG-stimulated B cells. However, at day 3 of stimula-
tion—coincident with the difference in cell size—XBP-1
 
 
 
/
 
 
 
cells showed a steep reduction in the level of IgM synthe-
sis, whereas XBP-1
 
 
 
/
 
 
 
 cells continued to increase their rate
of IgM synthesis (Fig. 2 A, compare lane 3 with lane 2 and
lane 6 with lane 5). We estimate that in XBP-1
 
 
 
/
 
 
 
 B cells
the level of synthesis of IgM per cell was reduced by 
 
 
 
15-
fold for LPS stimulation and sevenfold for CpG stimulation
by day 3 (Fig. 2 B). The kinetics for IgM secretion were re-
duced correspondingly in XBP-1
 
 
 
/
 
 
 
 cells (Fig. 2 C). Even
though ratios of 
 
 
 
 chain synthesis differed between CpG
and LPS stimulation, secretion rates of IgM were similar for
CpG- or LPS-treated XBP-1
 
 
 
/
 
 
 
 cells (Fig. 2 D). Hence,
XBP-1 was not required for the initial induction of 
 
 
 
 syn-
thesis in response to LPS or CpG stimulation, but partici-
pates later to support the up-regulation of IgM synthesis
Figure 2. High levels of biosynthesis and secretion of IgM require 
XBP-1. (A) 106 live cells, as determined by trypan blue exclusion, were 
pulse-labeled with [35S]methionine for 30 min. Cells were lysed in 1% SDS, 
and lysate was diluted to 0.07% SDS with NP-40 lysis mix followed by immu-
noprecipitation with anti-  antibodies and analysis by SDS-PAGE (10%). 
(B) Autoradiograms were quantified by phosphoimager. Empty bars, WT B 
cells; black bars, XBP1 /  B cells. (C) Cells stimulated for 3 d with LPS or CpG 
were pulse-labeled with [35S]methionine for 30 min and chased for up to
4 h. Cells were lysed in 1% SDS; lysate was diluted to 0.07% SDS with NP-40 
lysis mix followed by immunoprecipitation with anti-  antibodies. At each 
time point, IgM also was recovered from the media by immunoprecipitated 
with anti-  antibodies. Immunoprecipitates were analyzed by SDS-PAGE 
(10%). Each lane represents material from 106 live cells. (D) Autoradiograms 
were quantified by phosphoimager. Secreted   chains were expressed as 
percentage from   chains recovered after 4-h chase. (E) RNA was extracted 
from day 3 LPS-treated WT or XBP-1 /  B cells and analyzed by Northern 
blotting. Quantification indicates a 2.6-fold reduction in   mRNA levels in 
XBP-1 /  cells. (F) Semi-quantitative RT-PCR analysis of cDNA prepared 
from RNA of day 3 LPS-treated WT or XBP-1 /  B cells. Threefold dilution 
series of the cDNA were used as input material for the PCR with primers 
specific for   chains or GAPDH as a reference. The analysis indicates a less 
than threefold reduction in   mRNA levels in XBP-1 /  cells. 
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and to promote its secretion; these are consistent with the
proposed role for XBP-1 in driving the expansion of the
ER (11).
In the course of differentiation into plasma cells, the syn-
thesis of light chains is induced strongly to allow proper as-
sembly with the heavy chains. Therefore, we also measured
the effect of XBP-1 deficiency on the induction of synthesis
of the 
 
 
 
 light chain. B cells were cultured with CpG or LPS
for 3 d. Cells (1 
 
 
 
 10
 
6
 
) were pulse-labeled for 10, 20, or 30
min. The level of synthesis of 
 
 
 
 chains and 
 
 
 
 chains were
normalized to the synthesis of class I MHC product. Al-
though 
 
 
 
 chains were induced in the WT cells by 
 
 
 
10-15
fold for LPS and by approximately ninefold for CpG stimu-
lation, neither of these treatments resulted in an equivalent
induction of the 
 
 
 
 light chains (Fig. 3, C and D).
XBP-1 may exert control over 
 
 
 
 chain synthesis at the level
of transcription or by affecting posttranscriptional processes,
such as translation or targeting of nascent chains to the ER (17).
We compared, by semiquantitative PCR and Northern blot
analysis, the levels of 
 
 
 
 mRNA extracted from equal numbers
of live cells treated for 3 d with LPS. We observed only a slight
reduction in 
 
 
 
 transcript levels in XBP-1
 
 
 
/
 
 
 
 cells, as measured
by Northern blotting or by semiquantitative RT-PCR (Fig. 2,
E and F). We conclude that XBP-1 controls 
 
 
 
 chain synthesis
by a mechanism that is largely posttranscriptional.
 
XBP-1 does not affect the synthesis and trafficking of 
class I and class II MHC
 
Transcription profiling conducted for XBP-1 in B cells indi-
cates regulation over a large number of genes whose prod-
Figure 3. XBP-1 does not affect the synthesis of   light chain or 
synthesis and trafficking of class I and class II MHC. Cells stimulated 
for 3 d with CpG were pulse-labeled with [35S]methionine for 30 min and 
chased for up to 3 h. Cells were lysed in lysis buffer containing 0.5% 
NP-40. Under these conditions, MHC class I and class II complexes are 
preserved. (A) 90% of input were immunoprecipitated with P8 to recover 
H-2Kb. Class II I-A were immunoprecipitated with JV2 antibody. Immuno-
precipitates were analyzed by SDS-PAGE (10%). Note the nonspecific 
recovery of   chains only from WT cells. (B) 10% of input was immuno-
precipitated with anti-  antibodies. (C) Cells were stimulated for 3 d with 
CpG or LPS. 106 cells were pulse-labeled with [35S]methionine for 10, 20 or 
30 min. Cells were lysed in 1% SDS, and the lysate was diluted to 0.07% 
SDS with NP-40 lysis mix. 70% of lysis mix was immunoprecipitated with 
P8, 20% was immunoprecipitated with anti- , and 10% was immunopre-
cipitated with anti- . Immunoprecipitates were analyzed by SDS-PAGE 
(12%). (D) Autoradiograms were quantified by phosphoimager. Expression 
levels of   and   were normalized to the corresponding levels of H-2Kb. 
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ucts are implicated in different aspects of the secretory path-
way (4, 11). Therefore, the absence of XBP-1 was predicted
to affect the secretory pathway generally, rather than affect-
ing immunoglobulin synthesis and secretion specifically. We
examined the biosynthesis and trafficking of class I MHC
and class II MHC products to test this prediction. CpG-
stimulated B cells were pulse-labeled and MHC products
were recovered from them. In contrast to the 
 
 
 
 chains (Fig.
3 B), class I MHC heavy chains (HCs) were synthesized at
comparable levels in XBP-1
 
 
 
/
 
 
 
 and XBP-1
 
 /  cells (Fig. 3
A, top). Trafficking of HCs, as inferred from their N-linked
glycan modifications, was not affected by the absence of
XBP-1. We also followed the synthesis, assembly, and traf-
ficking of class II MHC products. Levels of class II MHC
synthesis also were similar in XBP-1 /  and XBP-1 /  cells.
Assembly of class II MHC with the invariant chain and mat-
uration of the complex, as assessed by the shift in electro-
phoretic mobility, were indistinguishable for both cell types
(Fig. 3 A, bottom).
We reach the conclusion that in primary B cells, XBP-1
specifically promotes the synthesis, maturation, and secretion
of IgM heavy chains, but not the synthesis and maturation of
other (glyco)proteins that enter the ER, such as classes I and
class II MHC, and Ig light chains. In addition, the trafficking
of class I and class II MHC products from the ER to the
Golgi complex is not affected by XBP-1. Had XBP-1 been
required to set the stage for glycoprotein synthesis generally,
then synthesis of IgM and MHC products should be affected
equally. Because nascent glycoproteins, regardless of their
identity, are held to use the same mechanism to gain access to
the ER, the similar levels of synthesis of MHC products ar-
gue against a general defect in cotranslational insertion into
the ER in the absence of XBP-1, and indicate a role for
XBP-1 in translation or ER function that is Ig-specific.
Degradation of ER proteins in plasmablasts does not 
require XBP-1
XBP-1 controls the expression of several genes that partici-
pate in the degradation of ER proteins. EDEM, an ER lec-
tin that is required for the degradation of several misfolded
ER proteins, is a specific target of XBP-1 (4). In mouse em-
bryonal fibroblasts that are deficient for XBP-1 or IRE1 ,
very little, if any, EDEM is present. In these cells, expression
of EDEM is restored only when XBP-1 levels are reconsti-
tuted. Thus far, EDEM is the only factor in mammalian cells
that directly links the UPR to ER degradation (14).
The human cytomegalovirus–encoded glycoprotein
US11 targets HCs for dislocation from the ER and degrada-
tion by the proteasome. When the proteasome is inhibited, a
deglycosylated HC intermediate accumulates in the cyto-
Figure 4. Degradation of ER proteins in plasmablasts does not 
require XBP-1. (A) Cells stimulated 24 h days with CpG were transduced 
with a retrovirus that encodes HLA-A2-IRES-US11 and incubated in 
the presence of CpG. 2 d after infection, cells were pulse-labeled with 
[35S]methionine for 20 min and chased for up to 80 min in the presence 
or absence of the proteasome inhibitor ZL3VS. Cells were lysed in 1% SDS; 
the lysate was diluted to 0.07% SDS with NP-40 lysis mix followed by 
immunoprecipitation with anti-class I heavy chain serum ( HC) and analysis 
by SDS-PAGE (12%). US11 was immunoprecipitated sequentially from the 
zero time point and similarly analyzed. (B) Autoradiograms were quantified 
as mentioned above and the deglycosylated HC/glycosylated HC ratio was 
calculated. (C) Similarly to (A), cells were transduced with a retrovirus that 
encodes TCR -IRES-YFP. Cells were pulse-labeled with [35S]methionine for 
20 min and chased for up to 2 h in the presence or absence of the protea-
some inhibitor ZL3VS. Cells were lysed in 1% SDS; the lysate was diluted to 
0.07% SDS with NP-40 lysis mix followed by immunoprecipitation with 
anti-TCR  and analysis by SDS-PAGE (12%). (D) Autoradiograms were 
quantified as mentioned above and the relative amount of TCR  to the 
zero time point was calculated.XBP-1 SPECIFICALLY PROMOTES   CHAIN SYNTHESIS IN PRIMARY B CELLS | Tirosh et al. 510
plasm. This pathway is emblematic of how mammalian cells
clear the ER of unwanted proteins. We previously investi-
gated US11-mediated degradation of HC in XBP-1 / 
mouse embryonal fibroblasts. Although the presence of XBP-1
was not essential, it did contribute to efficient degradation
of class I MHC products (18). Therefore, we tested US11-
mediated degradation of HC in XBP-1 /  B cells. To this
end, we constructed a bicistronic retroviral vector that ex-
presses US11 and the class I allele HLA-A2. This strategy en-
sures a fixed ratio between US11 and its cognate class I MHC
Figure 5. Membrane   is an endogenous substrate for degradation 
in  s /  B cell blasts. (A) J558L m cells were pulse-labeled with 
[35S]methionine for 30 min and chased for up to 4 h in the presence or 
absence of ZL3VS. Cells were lysed in 1% SDS; the lysate was diluted to 
0.07% SDS with NP-40 lysis mix followed by immunoprecipitation with 
anti-  antibodies. Where indicated, immunoprecipitates with EndoH 
which removes immature N-linked glycans. Immunoprecipitates were 
analyzed by SDS-PAGE (10%). (B)  s /  B cells stimulated for 4 d with LPS 
were pulse-labeled with [35S]methionine for 30 min and chased for up to
5 h.  -chains were analyzed as above. (C) Autoradiograms were quantified 
by phosphoimager, and the relative amount of   to the zero time point 
was calculated. (D)  s /  or  s /  BCL2 B cells were purified from sple-
nocytes by magnetic depletion with anti-CD43. Cells were plated at 
106 cells/ml, and stimulated with CpG. Flow cytometry analysis was 
performed, and live cells were gated based on their forward and side 
scattering. The percentage of dead cells is indicated. (E)  s /  BCL2 B cells 
stimulated for 4 d with LPS or CpG were pulse-labeled with [35S]methionine 
for 30 min and chased for up to 5 h.  -chains were analyzed as above. 
(F)  s /  BCL2 B cells were stimulated for 4 d with CpG or 2 d with 
CpG followed by 2 d with LPS (CpG/LPS). Cells were pulse-labeled with 
[35S]methionine for 30 min and chased for up to 5 h.  -chains were 
immunoprecipitated and analyzed as above. (G) Autoradiograms were 
quantified by phosphoimager, and the relative amount of   to the 1-h 
time point was calculated.JEM VOL. 202, August 15, 2005 511
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substrate in the primary B cells that are transduced, regardless
of their genotype. Pulse-chase analysis in the presence of the
proteasome inhibitor ZL3VS show that the conversion of gly-
cosylated HLA-A2 to the deglycosylated intermediate, as me-
diated by US11, is similar in XBP-1 /  and in WT B cells
(Fig. 4 A, lanes 7–12, quantified in Fig. 4 B). In the absence
of proteasome inhibitor, HLA-A2 was degraded rapidly (Fig.
4 A, lanes 4–6). We conclude that in B cells, XBP-1 is not
involved in US11-mediated degradation of HCs.
TCR , when expressed in the absence of the TCR 
chain, is misfolded and recognized as such by the ER quality
control machinery, and directed to proteasome-mediated deg-
radation (19, 20). We transduced the B cells with a TCR -
encoding retrovirus, and followed their degradation by pulse-
chase analysis. As expected, inclusion of the proteasome
inhibitor ZL3VS inhibited the degradation of TCR . Degrada-
tion rates of TCR  were similar in XBP-1 /  and XBP-1 / 
B cells (Fig. 4 C, quantified in Fig. 4 D). We conclude that
XBP-1 is not involved in the degradation of TCR .
Membrane   is an endogenous substrate for degradation in 
secretory   ( s) /  B cell blasts
Membrane IgM is presented at the cell surface in a complex
with Ig  and Ig  (21). Membrane   chain ( m), in which
the authentic transmembrane domain was replaced with that
of TCR , associates normally with the light chain, but un-
dergoes proteasome-mediated degradation (22). Therefore,
we assumed that in the absence of Ig  or Ig   m would be
retained in the ER and be subjected to dislocation and deg-
radation. For reference purposes, we followed the fate of  m
in the Ig -deficient myeloma cell line J558L reconstituted
with  m (J558L m). As anticipated,  m chains were re-
tained in the ER, as inferred from their EndoH sensitivity,
and were degraded by the proteasome, as indicated by their
stabilization in the presence of the proteasome inhibitor
ZL3VS (Fig. 5 A).
Upon mitogenic stimulation of B cells with LPS or CpG,
Ig , Ig , and  m are down-regulated, whereas secretory  
( s) and J-chain are strongly up-regulated (23, 24). The  s / 
mice, in which the last exon of secreted   and its poly ade-
nylation sites were deleted, cannot synthesize secretory IgM
(25). Therefore, we surmised that  s /  plasmablasts should
reach a stage where, for lack of Ig  and Ig ,  m will no
longer be assembled correctly, and is subject to ER degrada-
tion instead. Pulse-chase experiments conducted at day 4 of
LPS stimulation of purified B cells indicate that most of the
newly synthesized  m were retained in the ER, followed by
proteasome-mediated degradation (Fig. 5 B, quantified in
Fig. 5 C). We saw no evidence of class switch recombination
to other Ig isotypes as a means of escape from the toxicity of
accumulation of unassembled  m. In contrast to J558L m,
some of the synthesized  m appeared as a more diffuse band
of higher apparent molecular weight than the  m seen at
time zero. These polypeptides correspond to   chains that
successfully exited the ER and underwent complex-type
N-linked glycan modifications in the Golgi complex, as indi-
cated by their EndoH resistance (Fig. 5 B, lanes 7–8).
To investigate a possible role of XBP-1 in the degrada-
tion of misassembled  m in primary B cells, we expressed
XBP-1s by retroviral transduction in B cells prestimulated
for 24 h with CpG. The virus contains an internal ribosome
entry site (IRES)-GFP element that allows sorting of GFP-
positive cells 24 h after infection. For XBP-1s to exert its ef-
fects, we allowed an additional 48 h of expression. Using this
protocol, we were left repeatedly with viable cells at num-
bers too low to allow biochemical analysis. This is probably
due to the poor survival of B cells at day 4 after extraction
(Fig. 1), and the negative effect of overexpressed XBP-1s on
cell viability (unpublished data). Therefore, we reasoned that
crossing the  s /  mice to BCL2 transgenic (BCL2Tg) mice
should improve B cell survival, and provide protection from
XBP-1s–mediated cell death.
Degradation of  m in  s /    BCL2 B cell blasts
We isolated  s /    BCL2Tg B cells and stimulated them
with LPS or CpG. As expected, the expression of BCL2
protected the B cells from cell death, and resulted in near
complete survival after 4 d in culture (Fig. 5 D). We exam-
ined the fate of newly synthesized  m by pulse-chase analysis.
More   chains left the ER for the Golgi complex in  s /   
BCL2Tg B cells than in  s /  B cells (Fig. 5, B and E, com-
pare top band). The type of stimulation (LPS or CpG)
provided to the cells influenced the ratio between immature
and mature   chains, an observation for which we have no
satisfactory explanation. In response to CpG stimulation,
most of the newly synthesized   chains acquired EndoH re-
sistance (Fig. 5 E). Regardless of the type of stimulation, the
ER-retained   chains decayed over time, similarly to what
was seen for  s /  B cells and J558L m.
We found that stimulation of the  s /    BCL2Tg B
cells with CpG was a prerequisite to obtain an adequate effi-
ciency of viral transduction. This is probably the result of
better induction of proliferation by CpG than by LPS (un-
published data). Therefore, to maximize the amount of ER-
retained    chains available for degradation and to ensure
high transduction efficiency, we stimulated B cells with CpG
for 48 h, followed by 48 h of stimulation with LPS (Fig. 5 F,
lanes 5–8 versus lanes 1–4). Inclusion of proteasome inhibi-
tor stabilized the ER-retained   chains (Fig. 5 F, lanes 13–
16, quantified in Fig. 5 G).
To examine the role of XBP-1 in the degradation of  ,
we transduced  s /     BCL2Tg B cells with XBP-1s–
IRES-GFP or GFP alone. GFP  cells were sorted  18 h af-
ter infection (Fig. 6 A, left). At this time, XBP-1s–expressing
B cells already showed an increased cell size as indicated by
the mean forward scatter of the GFP  population (Fig. 6 A,
right). After 2 d of LPS treatment, equal numbers of live cells
were pulse-labeled for 30 min and chased for up to 5 h. The
first sample was withdrawn after 1 h of chase—a time point
adequate to resolve the ER-retained   chains from theXBP-1 SPECIFICALLY PROMOTES   CHAIN SYNTHESIS IN PRIMARY B CELLS | Tirosh et al. 512
Golgi-modified chains by SDS-PAGE. Imposition of XBP-
1s expression increased the level of  m synthesis when com-
pared with transduction with GFP alone (Fig. 6 B, compare
lane 4 with lane 1). However, the rate of  m degradation, as
measured relative to the 1-h chase point, was unaffected
(Fig. 6 C). We conclude that in accordance with what was
seen for secretory IgM, XBP-1s promotes the synthesis of
 m, but is not involved in its degradation.
Enforced expression of XBP-1s does not affect  m turnover
Finally, we examined whether overexpression of XBP-1s
would improve the capacity of the primary B cells to handle
unphysiologic levels of misfolded proteins. To this end, we
designed a pulse-chase experiment that incorporates 45 min
of tunicamycin treatment, as a means to generate a pool of
nonglycosylated, unfolded proteins in the ER. This was
followed by the addition of cycloheximide to block the
possibility of de novo synthesis of endogenous XBP-1 in the
 s /  BCL2 cells. Under these conditions,  50% of newly
synthesized   is nonglycosylated (Fig. 6 D, lanes 1 and 4);
this value indicates the efficacy of tunicamycin treatment.
Hence, in these tunicamycin-treated cells, the ER should
contain a far greater quantity of misfolded protein than what
is present in control cells. We measured the turnover of
nonglycosylated   when tunicamycin was added during the
pulse and the entire chase. We found no difference between
XBP-1s–transduced cells and GFP controls (Fig. 6 E). Next,
we tested the effect of tunicamycin treatment in the course
of the chase on the degradation of ER-retained fully glyco-
sylated  . This protocol was applied to explore whether the
turnover of preexisting   chains would be affected if a UPR
were induced later. Again, kinetics of turnover were highly
comparable for XBP-1s–transduced cells and GFP controls
(Fig. 6 F).  m degradation was affected minimally by tunica-
mycin treatment (compare Fig. 6, C and F), which suggested
that the ER degradation machinery in B cells was not satu-
rated. We conclude that XBP-1 is not required for the deg-
radation of   chains, even under conditions of nonphysio-
logic levels of misfolded proteins.
DISCUSSION
The IRE1/XBP-1 arm of the mammalian UPR was sug-
gested to coordinate the protein folding capacity and the
degradation machinery of the ER (14). In yeast, the UPR is
Figure 6. XBP-1 does not affect degradation of endogenous mem-
brane  . B cells stimulated for 24 h with CpG and transduced with XBP-1s-
IRES-GFP or IRES-GFP encoded retroviruses. 1 d later, the GFP-positive 
population was sorted, and plated for 2 d in the presence of LPS. (A) Flow 
cytometry analysis was performed at the time of sorting ( 18 h after 
infection). GFP-positive B cells are depicted in green. The mean forward 
scatter of GFP the positive population is indicated. (B) Equal numbers of 
live cells were pulse-labeled with [35S]methionine for 30 min and chased 
for up to 5 h.  -chains were immunoprecipitated and analyzed as above. 
(C) Autoradiograms were quantified by phosphoimager, and the relative 
amount of   to the 1-h time point was calculated. (D)  s  /  BCL2 B cells 
were stimulated and infected as in (A). Tunicamycin (1  g/ml) was added 
during the pulse-labeling period (left), or immediately after removal of the 
1-h chase point (right period). Cycloheximide was added at the initiation 
of the chase (left) or 45 min after tunicamycin addition (right). M-chains 
were immunoprecipitated and analyzed as above. (E) Autoradiograms 
were quantified by phosphoimager, and the relative amount of nonglyco-
sylated   to the zero time point was calculated. (F) Autoradiograms were 
quantified as above and the relative amount of immature   to the 1-h 
time point was calculated.JEM VOL. 202, August 15, 2005 513
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a key regulator of the protein folding capacity of the ER and
also of the ER degradation machinery. When engaged in re-
sponse to ER stress, the UPR augments the folding capacity
of the ER and simultaneously ensures the degradation of
misfolded ER proteins (12, 13). Augmentation of the pro-
tein-folding capacity in the ER and facilitation of the degra-
dation of misfolded ER cooperate to reduce the levels of
misfolded proteins in the ER. Therefore, these two pro-
cesses are intimately linked and share important molecular
components. For example, the ER-resident protein disulfide
isomerase assists in protein folding by catalyzing disulfide
bond formation, and is reported to participate in ER reten-
tion and dislocation of misfolded proteins (26); Bip and its
yeast equivalent Kar2p are chaperones necessary for protein
translocation into the ER and protein folding, and are also
key elements in the process of ER quality control and ER
degradation (27).
Thus far, the knowledge obtained for the biologic activ-
ity of XBP-1 is based mostly on experiments that provoke
extreme nonphysiologic conditions, such as treatment with
reagents that massively disrupt protein folding (tunicamycin),
or overexpression of XBP-1s. These studies ascribed differ-
ent roles to XBP-1, including the biogenesis of ER mem-
brane (8), up-regulation of protein folding in the ER, an in-
crease in lysosome and mitochondria content, and playing a
central role in the degradation of ER proteins (11, 14). The
mere presence of a misfolded protein fails to induce the
UPR to the extent seen when tunicamycin is used (12). To
our knowledge, there are very few data on glycoprotein
quality control in cultures of primary cells, and most evi-
dence has been gathered for permanently established cell
lines. We chose differentiating B cells as the model with
which to explore this issue for primary nontransformed cells.
We examined the role of XBP-1 under physiologic in-
duction of the UPR, such as differentiation of B lympho-
cytes into plasma cells (28, 29). Examination of   chain bio-
synthesis showed that XBP-1 was not required for the
induction of IgM synthesis in response to CpG or LPS stim-
ulation—a response probably linked to the activation of NF-
 B through Toll-like receptors—or for the engagement of
other signaling pathways. At later times, XBP-1 was re-
quired to sustain high levels of IgM synthesis because in the
absence of XBP-1, synthesis and secretion of   chains were
attenuated over 3 d of stimulation (Fig. 2); these suggested
possible XBP-1 control over assembly and trafficking of
IgM. The assembly of IgM monomers into pentamers was
normal in XBP-1 /  B cells (unpublished data).
In response to stimulation of splenic B cells with LPS and
CpG, splicing of XBP-1 mRNA occurs after 48 h. Using a
conditional allele of  , excision of the   locus strongly re-
duced XBP-1 splicing (28). Therefore, XBP-1 splicing re-
quires the expression of   heavy chains. Furthermore, pro-
teomic analysis of the B cell line, i.29   subjected to LPS
stimulation, revealed detectable levels of XBP-1s only after
induction of IgM synthesis (9). Accumulation of   chains in
the ER is the major trigger of IRE1 activation and subse-
quent XBP-1 mRNA splicing in B cells. In contrast, analysis
of the time course of IgM synthesis and XBP-1 splicing in
the B cell line, CH12 stimulated with LPS, indicated that
splicing of XBP-1 preceded IgM up-regulation (29). Our re-
sults show that XBP-1 is not required for the initial induc-
tion of IgM synthesis, but does plays a role later in sustaining
high levels of IgM synthesis. IgM synthesis and XBP-1 acti-
vation are part of a positive feedback loop in primary B cells
in the course of differentiation into plasma cells.
Reimold et al. reported minor changes in transcription
of the IgH locus after 4 d of LPS treatment of XBP1-1 / 
and XBP-1 /  B cells, as measured by RT-PCR (1). Gene
chip analysis that compared the transcriptome of XBP-1 / 
B cells with WT controls in response to LPS showed in-
creased levels of   transcripts in the WT cells (11). To re-
solve these differences, we analyzed the   mRNA levels,
and found no more than a twofold reduction of   transcripts
in XBP-1 /  cells (Fig. 2, E and F). This moderate reduc-
tion in mRNA levels cannot account for the dramatic re-
duction in   synthesis in XBP-1 /  B cells (Fig. 2 B). Our
data also are in agreement with the observation that trans-
duction of splenic B cells with a dominant negative allele of
ATF6 attenuates IgM secretion with minimal effect on  
transcription (30). Combined, these results suggest that post-
transcriptional mechanisms control the rate of IgM synthesis
in an XBP-1–dependent manner. The mechanism by which
XBP-1 controls IgM synthesis does not result in general
modulation of translation and insertion into the ER, because
genes introduced by retroviral transduction were synthesized
at comparable levels, and the endogenous immunoglobulin
light chains, class I MHC, and class II MHC products con-
tinued to be synthesized and transported intracellularly at
similar rates in both genetic backgrounds (Figs. 3 and 4).
These findings rule out the phosphorylation of eIF2  by
PERK as a plausible explanation for IgM down-regulation
in the XBP-1 /  B cells, because this phosphorylation re-
sults in general attenuation of translation initiation.
Cotranslational insertion of nascent proteins into the ER
is a process that involves several steps (for review see refer-
ence 31). Upon emergence from the ribosome, the signal
peptide is recognized instantly by the signal recognition parti-
cle (SRP). The SRP-bound signal peptide interacts with the
SRP receptor at the cytosolic face of the ER membrane. At
the ER, the signal peptide is transferred—by a poorly under-
stood mechanism—into the Sec61 translocon, the entry
channel into the ER (32). The fidelity with which proteins
enter the ER varies greatly between different signal peptides
and between different cell types (17). Therefore, it is possible
that XBP-1 in B cells controls specifically the efficiency by
which nascent   chains are targeted into the ER. By avoiding
general inhibition of translation, B cells ensure a continuous
increase in the flux of   chains that enter the ER. The accu-
mulation of   chains in the ER lumen promotes the splicing
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by fact that XBP-1 in B cells promotes the transcription of
several genes whose products participate in cotranslational in-
sertion of proteins into the ER, such as TRAM and compo-
nents of SRP and Sec61 themselves (4, 11, 33).
Transcriptional profiling of B cell indicates control by
XBP-1 over components of the ER degradation pathway. In
response to LPS, B cells up-regulate several genes whose
products are implicated in ER quality control, such as
EDEM and the mouse homologues of the yeast Hrd1 and
Hrd3. This response is attenuated severely in XBP-1 /  cells
(11). We have obtained compelling evidence for the in-
volvement of human Hrd1 and Hrd3 in the US11-depen-
dent pathway of class I MHC turnover, through direct phys-
ical interaction with Derlin-1 (Lilley, B.N. & Ploegh, H.L.,
unpublished data). However, it is not known whether XBP-1
contributes to the degradation of misfolded ER proteins.
Thus, we examined the capacity of XBP-1 /  B cells to de-
grade two well-characterized substrates for ER degradation.
The human CMV–encoded glycoprotein US11 reduces the
half-life of class I MHC HCs from hours to minutes by cata-
lyzing their dislocation. When we expressed HLA-A2 and
US11 in primary B cells, we observed comparable and ro-
bust dislocation of the class I MHC HC in XBP-1 /  and
XBP-1 /  B cells (Fig. 4). B cells are equipped in a manner
that does not require XBP-1 with the molecular machinery,
such as Derlin-1 and associated factors, to degrade HCs.
Similar results were obtained when we examined the
degradation of TCR . When expressed in primary B cells,
TCR  was degraded efficiently at rates superior to those
measured in COS-1 cells (19, 20) or U373 cells (34). This
degradation machinery operates independently of XBP-1
status (Fig. 4). We conclude that XBP-1 does not play an
important role in the degradation of ER proteins in B cells.
The UPR paradigm, as invoked for clearing the ER of un-
wanted proteins, may not apply to B cells. When the UPR is
induced by stimulation of CH12 cells with LPS, XBP-1 is
spliced; ER chaperones are induced; but the proapoptotic
gene CHOP, a UPR indicator, is not activated (29). The
UPR in B cells might be unusual, in that it supports induc-
tion of genes that facilitate IgM synthesis and secretion, but
fails to induce apoptosis.
Overexpression of XBP-1s in B cell lines induces the ex-
pression of genes that participate in protein translocation into
the ER, protein folding in the ER, and trafficking in the
secretory pathway (4, 11). Expression of XBP-1s in Raji
cells also yielded an increase in protein translation and a
marked decrease in total degradation of glycosylated pro-
teins; these probably are attributable to an increase in the
folding capacity of the ER (11). Because  m is recognized
for degradation due to a failure to assemble with Ig  and Ig 
rather than owing to the misfolding of   chains themselves,
an increase in the folding capacity of the ER as induced by
XBP-1s should not rescue  m from degradation. Therefore,
we hypothesized that enforced expression of XBP-1s should
facilitate the degradation of  m if XBP-1 is involved in this
degradation pathway. Expression of XBP-1s increases the
synthesis of  m by 20–70%, which supports our previous re-
sults that XBP-1 promotes IgM synthesis. Nonetheless, the
kinetics of degradation of  m remained unaltered (Fig. 6 C).
When we imposed a UPR by treatment with tunicamycin,
enforced expression of XBP-1s did not affect the rate of deg-
radation of  m chains (Fig. 6, E and F). Overall, our data in-
dicate a minor role, if any, for XBP-1 in ER quality control
in primary B cell blasts.
Why do XBP-1 /  B cells fail to yield plasma cells in
vivo? Two alternative mechanisms may apply. Either XBP-
1 /  B cells do not differentiate into plasma cells or XBP-
1 /  B plasma cells fail to survive. Because XBP-1 has been
postulated to be involved in the control of degradation of
protein in the ER, a failure of XBP-1 /  B cells to handle
those substrates could render them susceptible to apoptosis.
Our data argue against this hypothesis and indicate that,
in contrast to other cell types, primary plasmablasts are
equipped with highly efficient ER degradation machinery
that operates independently of XBP-1.
MATERIALS AND METHODS
Mice. We obtained 129S6 mice from Taconic. BCL2 Tg mice were pro-
vided by K. Rajewsky (Harvard Medical School, Boston, MA).  s /  and
 s /    BCL2 Tg mice were used at 6–8 wk and maintained in the patho-
gen-free facilities in accordance with the guidelines of the Committee on
Animals of Harvard Medical School.
Cell culture and cell lines. Mature B cells were purified from mouse
splenocytes by magnetic depletion with anti-CD43 (Miltenyi Biotech). Cells
were plated at 106 cells/ml in complete medium containing RPMI 1640
supplemented with 10% FBS (Hyclone Laboratories), 2 mM glutamine, 50
U/ml penicillin, 50  g/ml of streptomycin, 50  M of  -ME, 25 mM
Hepes, 1  nonessential amino acids, and 1 mM sodium pyruvate. Stimula-
tion was performed with 20  g/ml LPS (Sigma-Aldrich) or 100 nM of CpG
(1826-CPG, TIB Molbiol). J558L m were provided by J. Haimovich (Tel-
Aviv University, Tel Aviv, Israel) and maintained in the same medium.
Metabolic labeling, pulse-chase analysis, and immunoprecipitation.
After starvation in methionine/cysteine-free Dulbecco’s modified Eagle’s
medium for 45 min, cells were labeled metabolically with 500  Ci/ml of
[35S]methionine/cysteine (1,200 Ci/mmol, PerkinElmer) at 37 C for the
times indicated. Pulse-chase experiments, cell lysis, and immunoprecipita-
tion were performed as described previously (35). The immunoprecipitates
were analyzed by SDS-PAGE followed by fluorography. Densitometry was
performed by phosphorimager using Imagequant 1.0 software (Molecular
Dynamics). Antibodies against HCs, US11, and anti– -chain of class II
MHC have been described (36, 37). Goat anti–mouse I was purchased from
Southern Biotechnology. All of the experiments were conducted at least
three times with similar outcomes. Each figure shows a representative ex-
periment with the corresponding quantitation.
Northern hybridization and semi-quantitative RT-PCR. Total RNA
was isolated using TriZol (GIBCO BRL) or Qiashedder/Rneasy RNA
purification columns (QIAGEN). Northern blotting was performed as de-
scribed (28). In brief, 7–10  g RNA were electrophoresed on 1.2% aga-
rose, 6% formaldehyde gels transferred onto Genescreen membrane (NEN)
and covalently bound to the membrane using UV Stratalinker (Stratagene).
Probe for Cmu (CmuXB) was prepared as described (38). Hybridization
was performed with Ultrahyb buffer as recommended by the manufacturer
(Ambion). Total RNAs were used for first-strand synthesis with SuperscriptJEM VOL. 202, August 15, 2005 515
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reverse-transcriptase (Invitrogen). IgM PCR primers were used as described
(1). Three-fold dilutions of total cDNA were used for PCR amplification,
performed with AmpliTaq Gold polymerase (Applied Biosystem). PCR
products were electrophoresed on a 1% agarose gel and visualized by ethid-
ium bromide staining. Primers and probe were provided by J. Manis (Chil-
dren’s Hospital, Boston, MA).
RT-PCR analysis. Total RNA was isolated using TriZol (GIBCO
BRL). RNAs were used for first-strand synthesis with the Superscript re-
verse transcriptase (Invitrogen). PCR primers 5 -ACACGCTTGG-
GAATGGACAC-3  and 5 -CCATGGGAAGATGTTATGGG-3 , en-
compassing the missing sequences in XBP-1, were used for the PCR
amplification with Platinum PCR Supermix (Invitrogen). Cycling condi-
tions were as follows: 95 C for 3 min and 58 C for 40 s, 35 cycles of 72 C
for 45 s, and 95 C for 45 s. A PCR for GAPDH was performed to validate
cDNA synthesis. We separated PCR products by electrophoresis in 11%
PAGE gel and visualized them by ethidium bromide staining.
Retroviral transduction of B cells. The XBP-1s vector has been de-
scribed (28). cDNAs encoding TCR  were inserted into the GFP-RV ret-
roviral vector using double blunt ligation. HLA-A2-IRES-US11 was cloned
into the RV retroviral vector. We used Effectene transfection (QIAGEN) to
cointroduce the retroviral DNA and packaging vectors ENV and Gag-Pol
into 293T HEK cells in a 2:1:1 ratio. Viral supernatants were collected after
72 h and frozen at  80 C for later use. Purified B cells were stimulated for
24 h with CpG and spin-infected with virus-containing supernatants supple-
mented with 4  g/ml polybrene. Cells were incubated for 24 h, washed,
and replated at 106 cells/ml. Where indicated, GFP-positive cells were sorted
by flow cytometry. Pulse-chase experiments were performed 72 h after stim-
ulation or 4 d after stimulation for the BCL2 transgenic cells.
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